Published in Mov Disord on February 14, 2014
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol (2014) 1.89
Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther (2014) 1.77
Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy. Circ Res (2016) 1.05
Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging. Theranostics (2016) 0.84
Clinical trials: past, current, and future for atypical Parkinsonian syndromes. Semin Neurol (2014) 0.83
Glycogen synthase kinase-3: A potential preventive target for prostate cancer management. Urol Oncol (2015) 0.82
Nuclear GSK3β promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22. Nat Cell Biol (2016) 0.82
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. Biomed Res Int (2016) 0.81
Targeting hepatic glucose metabolism in the treatment of type 2 diabetes. Nat Rev Drug Discov (2016) 0.80
Treatment of frontotemporal dementia. Curr Treat Options Neurol (2014) 0.79
Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy. Mov Disord (2016) 0.79
Key emerging issues in progressive supranuclear palsy and corticobasal degeneration. J Neurol (2015) 0.78
A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity. Mol Cancer Ther (2016) 0.78
Promotion of natural tooth repair by small molecule GSK3 antagonists. Sci Rep (2017) 0.78
Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease. Curr Neuropharmacol (2016) 0.77
Clinical Approach to Progressive Supranuclear Palsy. J Mov Disord (2016) 0.77
PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy. J Neurol (2016) 0.76
Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology (2016) 0.76
Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. Alzheimers Dement (2016) 0.76
A Four-Point Screening Method for Assessing Molecular Mechanism of Action (MMOA) Identifies Tideglusib as a Time-Dependent Inhibitor of Trypanosoma brucei GSK3β. PLoS Negl Trop Dis (2016) 0.76
Managing cognition in progressive supranuclear palsy. Neurodegener Dis Manag (2016) 0.75
Therapy and clinical trials in frontotemporal dementia: past, present, and future. J Neurochem (2016) 0.75
Sample size calculations for clinical trials targeting tauopathies: a new potential disease target. J Neurol (2015) 0.75
Minimal clinically important worsening on the progressive supranuclear Palsy Rating Scale. Mov Disord (2016) 0.75
Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. Parkinsonism Relat Disord (2016) 0.75
Synthesis of Diverse (11)C-Labeled PET Radiotracers via Direct Incorporation of [(11)C]CO2. Bioconjug Chem (2016) 0.75
Emerging Diagnostic and Therapeutic Strategies for Tauopathies. Curr Neurol Neurosci Rep (2017) 0.75
Freezing of gait is an early clinical feature of progressive supranuclear palsy. Neurol Clin Neurosci (2017) 0.75
Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau. Mayo Clin Proc (2017) 0.75
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis (2006) 5.96
Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med (2004) 4.56
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain (2009) 4.01
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol (2009) 3.55
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet (2010) 3.34
Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol (2008) 3.03
Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet (2011) 2.97
Dementia with Lewy bodies. Lancet Neurol (2004) 2.66
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy. Dement Geriatr Cogn Disord (2010) 2.49
The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis (2006) 2.42
Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain (2005) 2.34
Social networks, social integration, and social engagement determine cognitive decline in community-dwelling Spanish older adults. J Gerontol B Psychol Sci Soc Sci (2003) 2.31
Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol (2009) 2.28
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study. BMC Med (2008) 2.10
High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet (2005) 2.08
Lrrk2 and Lewy body disease. Ann Neurol (2006) 2.00
Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study. Arch Neurol (2006) 1.94
Life with communication changes in Parkinson's disease. Age Ageing (2006) 1.90
Differential regulation of IgG anti-capsular polysaccharide and antiprotein responses to intact Streptococcus pneumoniae in the presence of cognate CD4+ T cell help. J Immunol (2004) 1.90
Validation of a short cognitive tool for the screening of dementia in elderly people with low educational level. Int J Geriatr Psychiatry (2003) 1.83
Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with lewy bodies. Am J Psychiatry (2004) 1.82
The genetics of Parkinson's syndromes: a critical review. Curr Opin Genet Dev (2009) 1.79
The structure of the tau haplotype in controls and in progressive supranuclear palsy. Hum Mol Genet (2004) 1.72
Activation of the subventricular zone in multiple sclerosis: evidence for early glial progenitors. Proc Natl Acad Sci U S A (2007) 1.71
Attention to action in Parkinson's disease: impaired effective connectivity among frontal cortical regions. Brain (2002) 1.70
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis Assoc Disord (2008) 1.63
A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann Neurol (2006) 1.61
Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol (2002) 1.61
Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord (2007) 1.55
Hyperkalaemia in a tetraplegic adolescent due to de novo sodium channel mutation. Nephrol Dial Transplant (2007) 1.50
Alzheimer's disease presenting as corticobasal syndrome. Mov Disord (2006) 1.46
Independent domains of gait in older adults and associated motor and nonmotor attributes: validation of a factor analysis approach. J Gerontol A Biol Sci Med Sci (2012) 1.45
Volumetric correlates of cognitive functioning in nondemented patients with Parkinson's disease. Mov Disord (2013) 1.45
PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine. Neurology (2012) 1.44
Aggressive course of disease in dementia. Alzheimers Dement (2006) 1.44
Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: the GenePD study. Mov Disord (2008) 1.41
Penguins and hummingbirds: midbrain atrophy in progressive supranuclear palsy. Neurology (2006) 1.40
Adherence to antiparkinson medication in a multicenter European study. Mov Disord (2009) 1.34
Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol (2004) 1.33
Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest (2013) 1.32
Dopamine and adult neurogenesis. J Neurochem (2006) 1.31
Salmonella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. enteritidis. Infect Immun (2011) 1.29
Phosphorylated α-synuclein in Parkinson's disease. Sci Transl Med (2012) 1.29
Patients with a novel neurofilamentopathy: dementia with neurofilament inclusions. Neurosci Lett (2003) 1.27
Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cogn Disord (2003) 1.27
An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. Acta Neuropathol (2006) 1.24
Identification of a novel risk locus for progressive supranuclear palsy by a pooled genomewide scan of 500,288 single-nucleotide polymorphisms. Am J Hum Genet (2007) 1.24
Trajectories of cognitive decline and social relations. J Gerontol B Psychol Sci Soc Sci (2005) 1.22
The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord (2014) 1.20
Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp Neurol (2007) 1.20
Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease. Neuroimage (2004) 1.19
Hard to swallow: dysphagia in Parkinson's disease. Age Ageing (2006) 1.19
Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain (2011) 1.18
Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain (2012) 1.18
Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J Neurosci (2007) 1.18
Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease. Mov Disord (2010) 1.17
Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord (2009) 1.15
A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Mov Disord (2010) 1.13
Progression of gait, speech and swallowing deficits in progressive supranuclear palsy. Neurology (2003) 1.12
Screening for VPS35 mutations in Parkinson's disease. Neurobiol Aging (2011) 1.12
Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry (2005) 1.11
Rational therapeutic approaches to progressive supranuclear palsy. Brain (2010) 1.11
Parkinsonism and dystonia caused by the illicit use of ephedrone--a longitudinal study. Mov Disord (2008) 1.11
Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. Neuroimage (2004) 1.10
More severe functional impairment in dementia with lewy bodies than Alzheimer disease is related to extrapyramidal motor dysfunction. Am J Geriatr Psychiatry (2006) 1.10
The pattern of habitual sedentary behavior is different in advanced Parkinson's disease. Mov Disord (2010) 1.09
A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord (2010) 1.09
Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. J Neurochem (2004) 1.08
The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features. Neurobiol Aging (2012) 1.07
A peptide mimotope of type 8 pneumococcal capsular polysaccharide induces a protective immune response in mice. Infect Immun (2005) 1.07
Milestones in Parkinson's disease--clinical and pathologic features. Mov Disord (2011) 1.07
Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. J Alzheimers Dis (2013) 1.06
Cognitive decline is related to education and occupation in a Spanish elderly cohort. Aging Clin Exp Res (2002) 1.05
Gait variability in Parkinson's disease: an indicator of non-dopaminergic contributors to gait dysfunction? J Neurol (2010) 1.05
Dopaminergic substantia nigra neurons project topographically organized to the subventricular zone and stimulate precursor cell proliferation in aged primates. J Neurosci (2006) 1.04
Clinical and pathological features of an Alzheimer's disease patient with the MAPT Delta K280 mutation. Neurobiol Aging (2007) 1.03
Cognitive impairment in nondemented Parkinson's disease. Mov Disord (2011) 1.01
Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Mov Disord (2005) 1.01
Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease. Exp Neurol (2012) 1.00
Measuring mild cognitive impairment in patients with Parkinson's disease. Mov Disord (2013) 1.00
Parameters underlying distinct T cell-dependent polysaccharide-specific IgG responses to an intact gram-positive bacterium versus a soluble conjugate vaccine. J Immunol (2009) 1.00
Executive dysfunction and attention contribute to gait interference in 'off' state Parkinson's Disease. Gait Posture (2009) 0.99
Familial Parkinsonism and early onset Parkinson's disease in a Brazilian movement disorders clinic: phenotypic characterization and frequency of SNCA, PRKN, PINK1, and LRRK2 mutations. Mov Disord (2009) 0.99
Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord (2014) 0.99